It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Polo-like kinase 1 (Plk1) is instrumental for mitotic entry and progression. Plk1 is activated by phosphorylation on a conserved residue Thr210 in its activation segment by the Aurora A kinase (AURKA), a reaction that critically requires the co-factor Bora phosphorylated by a CyclinA/B-Cdk1 kinase. Here we show that phospho-Bora is a direct activator of AURKA kinase activity. We localize the key determinants of phospho-Bora function to a 100 amino acid region encompassing two short Tpx2-like motifs and a phosphoSerine-Proline motif at Serine 112, through which Bora binds AURKA. The latter substitutes in trans for the Thr288 phospho-regulatory site of AURKA, which is essential for an active conformation of the kinase domain. We demonstrate the importance of these determinants for Bora function in mitotic entry both in Xenopus egg extracts and in human cells. Our findings unveil the activation mechanism of AURKA that is critical for mitotic entry.
Tavernier et al. decipher the mechanism by which the intrinsically disordered protein Bora, phosphorylated by Cyclin-Cdk, potentiates AURKA activity towards Polo-like kinase 1. Furthermore, they demonstrate the importance of this mechanism for timely mitotic entry in Xenopus and human cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Canada (GRID:grid.250674.2) (ISNI:0000 0004 0626 6184); Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.250674.2)
2 Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.250674.2)
3 Centre de Recherche de Biologie cellulaire de Montpellier, UMR 5237, Université de Montpellier, CNRS, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
4 Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Canada (GRID:grid.250674.2) (ISNI:0000 0004 0626 6184)
5 Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, USA (GRID:grid.420089.7) (ISNI:0000 0000 9635 8082)
6 Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.420089.7)
7 University of Minnesota, Department of Pharmacology, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
8 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X)
9 Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.415224.4)
10 Institut Gustave Roussy CNRS UMR9019, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
11 Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.14925.3b)
12 Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, Canada (GRID:grid.250674.2) (ISNI:0000 0004 0626 6184); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Biochemistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
13 Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France (GRID:grid.17063.33)